Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention

The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. A total of 1724 p...

Full description

Saved in:
Bibliographic Details
Published inAnnals of medicine (Helsinki) Vol. 54; no. 1; pp. 1667 - 1677
Main Authors Han, Kangning, Shi, Dongmei, Yang, Lixia, Wang, Zhijian, Li, Yueping, Gao, Fei, Liu, Yuyang, Ma, Xiaoteng, Zhou, Yujie
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 31.12.2022
Taylor & Francis Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization. During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001). SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGES The SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention. Higher SIRI is associated with a more severe disease status. The SIRI could increase the prognostic value of the GRACE risk score.
AbstractList The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization. During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001). SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGES The SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention. Higher SIRI is associated with a more severe disease status. The SIRI could increase the prognostic value of the GRACE risk score.
The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.BACKGROUNDThe systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.OBJECTIVESThe aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.METHODSA total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).RESULTSDuring a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score.CONCLUSIONSIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score.
The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization. During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229  = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007,  = .040; net reclassification improvement: 0.175,  = .020; likelihood ratio test:  < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (  < .001). SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score.
Background The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.Objectives The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.Methods A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.Results During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034–1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).Conclusion SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score.
Author Wang, Zhijian
Ma, Xiaoteng
Gao, Fei
Liu, Yuyang
Han, Kangning
Li, Yueping
Yang, Lixia
Shi, Dongmei
Zhou, Yujie
Author_xml – sequence: 1
  givenname: Kangning
  surname: Han
  fullname: Han, Kangning
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 2
  givenname: Dongmei
  surname: Shi
  fullname: Shi, Dongmei
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 3
  givenname: Lixia
  surname: Yang
  fullname: Yang, Lixia
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 4
  givenname: Zhijian
  surname: Wang
  fullname: Wang, Zhijian
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 5
  givenname: Yueping
  surname: Li
  fullname: Li, Yueping
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 6
  givenname: Fei
  surname: Gao
  fullname: Gao, Fei
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 7
  givenname: Yuyang
  surname: Liu
  fullname: Liu, Yuyang
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 8
  givenname: Xiaoteng
  surname: Ma
  fullname: Ma, Xiaoteng
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
– sequence: 9
  givenname: Yujie
  surname: Zhou
  fullname: Zhou, Yujie
  organization: Beijing Institute of Heart, Lung and Blood Vessel Disease
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35695557$$D View this record in MEDLINE/PubMed
BookMark eNqFkttu1DAQhiNURLeFRwDlkpstPsSHCAlRVRwqVYILuLYcZ7x1ldiL7WzZp-CVcci2UC7gZiyNv_lnPP5PqiMfPFTVc4zOMJLoFRKSUdmiM4IIKUFSLvCjaoUpZ2uCODqqVjOznqHj6iSlG4QQERg9qY4p4y1jTKyqH59j2PiQsjP1Tg8T1MHWaZ8yjCXjvB30OOoc4r6OkLbBJyjZHr6XWG91duBzqm9dvq61mTLUJsTgdcHT3vcxjFBPBY-b4Pym3kIskPYQpvSbdD5D3BUhF_zT6rHVQ4Jnh_O0-vr-3ZeLj-urTx8uL86v1obRJq8157LpGAUjpZBSMwa4pdJKogUG1HPbCIslNJZ3QCwFiXrTdh3HXa8paulpdbno9kHfqG10Y5lEBe3Ur0SIG6VjWcoAqsMUYY4Ea6BpLOq16UnH2g432hrRyqL1ZtHaTt0IvSkviXp4IPrwxrtrtQk71RLCBMFF4OVBIIZvE6SsRpcMDMOyKUW4YK1sRDujL_7sdd_k7kcLwBbAxJBSBHuPYKRm56g756jZOergnFL3-q8647Kev6SM7Ib_Vr9dqotjQhz1bYhDr7LeDyHaqL1xSdF_S_wEshrh6g
CitedBy_id crossref_primary_10_1016_j_ajem_2025_02_025
crossref_primary_10_3233_JAD_230886
crossref_primary_10_3390_jpm13091408
crossref_primary_10_3390_ijms23179553
crossref_primary_10_3389_fcvm_2023_1284491
crossref_primary_10_3389_fendo_2023_1100453
crossref_primary_10_3390_jcm13206059
crossref_primary_10_1186_s12872_024_03763_9
crossref_primary_10_4103_bc_bc_32_24
crossref_primary_10_1016_j_isci_2023_108060
crossref_primary_10_1016_j_puhe_2022_10_005
crossref_primary_10_2147_JIR_S454117
crossref_primary_10_3390_jcm13051256
crossref_primary_10_1177_00033197241285970
crossref_primary_10_3390_biomedicines12051066
crossref_primary_10_31083_j_rcm2405153
crossref_primary_10_3389_fcvm_2024_1361088
crossref_primary_10_15829_1560_4071_20245823
crossref_primary_10_3389_fcvm_2024_1418781
crossref_primary_10_3389_fcvm_2022_1066219
crossref_primary_10_4103_tjem_tjem_198_23
crossref_primary_10_2147_JIR_S498292
crossref_primary_10_3390_cancers17060990
crossref_primary_10_1080_07853890_2023_2196438
crossref_primary_10_1186_s13098_024_01419_4
crossref_primary_10_2147_JIR_S421491
crossref_primary_10_1186_s12933_022_01627_0
crossref_primary_10_2147_JIR_S505797
crossref_primary_10_1016_j_heliyon_2024_e39029
crossref_primary_10_1080_07853890_2022_2104919
crossref_primary_10_1080_0886022X_2024_2330621
crossref_primary_10_1177_00033197231151564
crossref_primary_10_1186_s12872_022_02989_9
crossref_primary_10_1097_MD_0000000000036512
crossref_primary_10_1177_10815589241283739
crossref_primary_10_3389_fmed_2024_1404152
crossref_primary_10_3390_life13061395
crossref_primary_10_3390_jcdd12020079
crossref_primary_10_3389_fnut_2025_1540933
crossref_primary_10_1038_s41598_024_84759_5
crossref_primary_10_2147_JIR_S421021
crossref_primary_10_1186_s12872_024_04417_6
crossref_primary_10_2147_JIR_S432506
crossref_primary_10_3389_fimmu_2024_1324890
crossref_primary_10_1186_s12872_023_03403_8
crossref_primary_10_1002_iid3_70180
crossref_primary_10_1177_10760296231198042
crossref_primary_10_1186_s13578_024_01226_4
crossref_primary_10_2147_JIR_S435398
crossref_primary_10_7759_cureus_49391
crossref_primary_10_1111_eci_14332
crossref_primary_10_1177_00033197231158937
crossref_primary_10_1007_s00277_023_05518_6
crossref_primary_10_2147_JIR_S479253
crossref_primary_10_3390_jcdd10050199
crossref_primary_10_2174_011871529X269740231102045028
crossref_primary_10_31083_j_rcm2506202
crossref_primary_10_1016_j_toxicon_2023_107269
crossref_primary_10_1080_00015385_2023_2218020
crossref_primary_10_31083_j_rcm2312400
crossref_primary_10_2478_jce_2024_0014
crossref_primary_10_1002_iid3_1369
crossref_primary_10_1177_00033197231198678
Cites_doi 10.3389/fcvm.2021.755806
10.1016/j.amjcard.2017.06.020
10.1160/TH11-02-0096
10.3109/00365513.2013.860619
10.1056/NEJMra043430
10.1007/s00380-010-0010-7
10.1161/CIRCULATIONAHA.104.504159
10.1093/cvr/cvy130
10.1016/0002-8703(92)90942-O
10.1016/S0140-6736(17)32154-2
10.1371/journal.pone.0007947
10.1097/FJC.0b013e31829f716a
10.1067/mhj.2001.115792
10.1177/0003319713479154
10.1007/s00270-021-02965-4
10.1161/CIRCRESAHA.114.302699
10.1016/j.jacc.2009.04.021
10.1016/j.intimp.2018.10.002
10.1007/s10753-011-9384-7
10.1093/eurheartj/ehm004
10.1093/eurheartj/ehab221
10.1038/s41598-021-97678-6
10.1056/NEJMoa1809798
10.1016/j.atherosclerosis.2016.04.015
10.1007/s00395-016-0535-8
10.1097/MD.0000000000012813
10.2217/bmm-2017-0235
10.1038/s41569-019-0169-2
10.1177/0003319713497992
10.1089/dia.2013.0097
10.2147/JIR.S283835
10.1136/heart.89.10.1200
10.1002/clc.23749
10.1177/1076029621999717
10.2174/1381612824666180116100310
10.1002/cncr.30057
10.1016/j.ehj.2004.05.002
10.2174/138161207780487593
10.1159/000068448
10.1007/s13311-016-0483-x
10.1242/jcs.114.1.131
10.2147/CIA.S339221
10.1016/0002-9149(84)90624-6
10.1056/NEJMoa1707914
10.1007/s10067-022-06122-1
10.1186/s12872-017-0507-4
10.1007/s10157-012-0728-x
10.1161/ATVBAHA.110.209296
10.1016/S0002-9149(96)00878-8
10.1016/j.jacc.2020.08.011
10.1073/pnas.85.20.7462
10.1093/eurheartj/ehaa1034
10.1080/00325481.2020.1809870
10.3109/10641963.2012.758734
ContentType Journal Article
Copyright 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022
2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s)
Copyright_xml – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022
– notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s)
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1080/07853890.2022.2083671
DatabaseName Taylor & Francis Open Access (WRLC)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate K. Han et al
EISSN 1365-2060
EndPage 1677
ExternalDocumentID oai_doaj_org_article_b130160754e44f0dacd2b59b14afc798
PMC9225721
35695557
10_1080_07853890_2022_2083671
2083671
Genre Research Article
Journal Article
GroupedDBID ---
00X
03L
0YH
23M
36B
4.4
5GY
5RE
AALUX
ABLKL
ABUPF
ACENM
ACGEJ
ACGFS
ADCVX
ADRBQ
ADXPE
AENEX
AEOZL
AFKVX
AGYJP
AIJEM
AJWEG
ALMA_UNASSIGNED_HOLDINGS
BABNJ
BLEHA
BOHLJ
CCCUG
CS3
DKSSO
EBD
EBS
EMB
EMOBN
F5P
GROUPED_DOAJ
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M4Z
O9-
OK1
P2P
RPM
SV3
TDBHL
TFDNU
TFL
TFW
V1S
WH7
~1N
AAFWJ
AAYXX
CITATION
.55
.GJ
34G
39C
3O-
53G
5VS
AALIY
AAORF
AAPXX
ABWCV
ABZEW
ADFZZ
AFFNX
AFLEI
AJVHN
AWYRJ
BRMBE
CAG
CGR
COF
CUY
CVF
CYYVM
CZDIS
DRXRE
DWTOO
ECM
EIF
EJD
JENTW
M44
NPM
NUSFT
OVD
QQXMO
TEORI
X7M
ZGI
ZXP
7X8
5PM
ID FETCH-LOGICAL-c534t-a6684b53ec88788a55e1938f82a71e0d6f47f18e4f6be2f3e80dc9bb61bda3093
IEDL.DBID DOA
ISSN 0785-3890
1365-2060
IngestDate Wed Aug 27 01:12:08 EDT 2025
Thu Aug 21 14:11:54 EDT 2025
Thu Jul 10 19:29:19 EDT 2025
Thu Apr 03 07:04:27 EDT 2025
Tue Aug 05 12:07:51 EDT 2025
Thu Apr 24 22:53:10 EDT 2025
Wed Dec 25 09:05:38 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords percutaneous coronary intervention
acute coronary syndrome
cardiovascular outcomes
Systemic inflammatory response index
Language English
License open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-a6684b53ec88788a55e1938f82a71e0d6f47f18e4f6be2f3e80dc9bb61bda3093
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Supplemental data for this article is available online at https://doi.org/10.1080/07853890.2022.2083671.
OpenAccessLink https://doaj.org/article/b130160754e44f0dacd2b59b14afc798
PMID 35695557
PQID 2675984791
PQPubID 23479
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_b130160754e44f0dacd2b59b14afc798
crossref_primary_10_1080_07853890_2022_2083671
pubmed_primary_35695557
informaworld_taylorfrancis_310_1080_07853890_2022_2083671
proquest_miscellaneous_2675984791
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9225721
crossref_citationtrail_10_1080_07853890_2022_2083671
PublicationCentury 2000
PublicationDate 2022-12-31
PublicationDateYYYYMMDD 2022-12-31
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-31
  day: 31
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Annals of medicine (Helsinki)
PublicationTitleAlternate Ann Med
PublicationYear 2022
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_5_29_1
e_1_3_5_27_1
e_1_3_5_25_1
e_1_3_5_23_1
e_1_3_5_44_1
e_1_3_5_46_1
e_1_3_5_48_1
e_1_3_5_3_1
e_1_3_5_40_1
e_1_3_5_42_1
e_1_3_5_9_1
e_1_3_5_21_1
e_1_3_5_5_1
e_1_3_5_7_1
e_1_3_5_18_1
e_1_3_5_39_1
e_1_3_5_16_1
e_1_3_5_37_1
e_1_3_5_14_1
e_1_3_5_35_1
e_1_3_5_12_1
e_1_3_5_33_1
e_1_3_5_50_1
e_1_3_5_52_1
e_1_3_5_54_1
e_1_3_5_10_1
e_1_3_5_31_1
e_1_3_5_28_1
e_1_3_5_26_1
e_1_3_5_24_1
e_1_3_5_22_1
e_1_3_5_45_1
e_1_3_5_47_1
e_1_3_5_49_1
e_1_3_5_2_1
e_1_3_5_41_1
e_1_3_5_43_1
e_1_3_5_8_1
e_1_3_5_20_1
e_1_3_5_4_1
e_1_3_5_6_1
e_1_3_5_17_1
e_1_3_5_38_1
e_1_3_5_15_1
e_1_3_5_13_1
e_1_3_5_36_1
e_1_3_5_11_1
e_1_3_5_34_1
e_1_3_5_55_1
e_1_3_5_19_1
e_1_3_5_51_1
e_1_3_5_53_1
e_1_3_5_32_1
e_1_3_5_30_1
References_xml – ident: e_1_3_5_15_1
  doi: 10.3389/fcvm.2021.755806
– ident: e_1_3_5_33_1
  doi: 10.1016/j.amjcard.2017.06.020
– ident: e_1_3_5_27_1
  doi: 10.1160/TH11-02-0096
– ident: e_1_3_5_40_1
  doi: 10.3109/00365513.2013.860619
– ident: e_1_3_5_5_1
  doi: 10.1056/NEJMra043430
– ident: e_1_3_5_30_1
  doi: 10.1007/s00380-010-0010-7
– ident: e_1_3_5_9_1
  doi: 10.1161/CIRCULATIONAHA.104.504159
– ident: e_1_3_5_28_1
  doi: 10.1093/cvr/cvy130
– ident: e_1_3_5_6_1
  doi: 10.1016/0002-8703(92)90942-O
– ident: e_1_3_5_2_1
  doi: 10.1016/S0140-6736(17)32154-2
– ident: e_1_3_5_54_1
  doi: 10.1371/journal.pone.0007947
– ident: e_1_3_5_45_1
  doi: 10.1097/FJC.0b013e31829f716a
– ident: e_1_3_5_32_1
  doi: 10.1067/mhj.2001.115792
– ident: e_1_3_5_47_1
  doi: 10.1177/0003319713479154
– ident: e_1_3_5_38_1
  doi: 10.1007/s00270-021-02965-4
– ident: e_1_3_5_8_1
  doi: 10.1161/CIRCRESAHA.114.302699
– ident: e_1_3_5_24_1
  doi: 10.1016/j.jacc.2009.04.021
– ident: e_1_3_5_37_1
  doi: 10.1016/j.intimp.2018.10.002
– ident: e_1_3_5_3_1
  doi: 10.1007/s10753-011-9384-7
– ident: e_1_3_5_53_1
  doi: 10.1093/eurheartj/ehm004
– ident: e_1_3_5_50_1
  doi: 10.1093/eurheartj/ehab221
– ident: e_1_3_5_34_1
  doi: 10.1038/s41598-021-97678-6
– ident: e_1_3_5_52_1
  doi: 10.1056/NEJMoa1809798
– ident: e_1_3_5_12_1
  doi: 10.1016/j.atherosclerosis.2016.04.015
– ident: e_1_3_5_25_1
  doi: 10.1007/s00395-016-0535-8
– ident: e_1_3_5_35_1
  doi: 10.1097/MD.0000000000012813
– ident: e_1_3_5_44_1
  doi: 10.2217/bmm-2017-0235
– ident: e_1_3_5_4_1
  doi: 10.1038/s41569-019-0169-2
– ident: e_1_3_5_39_1
  doi: 10.1177/0003319713497992
– ident: e_1_3_5_41_1
  doi: 10.1089/dia.2013.0097
– ident: e_1_3_5_20_1
  doi: 10.2147/JIR.S283835
– ident: e_1_3_5_7_1
  doi: 10.1136/heart.89.10.1200
– ident: e_1_3_5_55_1
  doi: 10.1002/clc.23749
– ident: e_1_3_5_14_1
  doi: 10.1177/1076029621999717
– ident: e_1_3_5_51_1
  doi: 10.2174/1381612824666180116100310
– ident: e_1_3_5_17_1
  doi: 10.1002/cncr.30057
– ident: e_1_3_5_10_1
  doi: 10.1016/j.ehj.2004.05.002
– ident: e_1_3_5_21_1
  doi: 10.2174/138161207780487593
– ident: e_1_3_5_31_1
  doi: 10.1159/000068448
– ident: e_1_3_5_11_1
  doi: 10.1007/s13311-016-0483-x
– ident: e_1_3_5_22_1
  doi: 10.1242/jcs.114.1.131
– ident: e_1_3_5_18_1
  doi: 10.2147/CIA.S339221
– ident: e_1_3_5_26_1
  doi: 10.1016/0002-9149(84)90624-6
– ident: e_1_3_5_49_1
  doi: 10.1056/NEJMoa1707914
– ident: e_1_3_5_19_1
  doi: 10.1007/s10067-022-06122-1
– ident: e_1_3_5_43_1
  doi: 10.1186/s12872-017-0507-4
– ident: e_1_3_5_42_1
  doi: 10.1007/s10157-012-0728-x
– ident: e_1_3_5_29_1
  doi: 10.1161/ATVBAHA.110.209296
– ident: e_1_3_5_36_1
  doi: 10.1016/S0002-9149(96)00878-8
– ident: e_1_3_5_48_1
  doi: 10.1016/j.jacc.2020.08.011
– ident: e_1_3_5_23_1
  doi: 10.1073/pnas.85.20.7462
– ident: e_1_3_5_13_1
  doi: 10.1093/eurheartj/ehaa1034
– ident: e_1_3_5_16_1
  doi: 10.1080/00325481.2020.1809870
– ident: e_1_3_5_46_1
  doi: 10.3109/10641963.2012.758734
SSID ssj0002710
Score 2.6104345
Snippet The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. The aim of this study was to examine the association...
The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.BACKGROUNDThe systemic inflammatory response index (SIRI) is...
Background The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.Objectives The aim of this study was to examine...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1667
SubjectTerms acute coronary syndrome
Acute Coronary Syndrome - complications
Cardiology & Cardiovascular Disorders
cardiovascular outcomes
Humans
percutaneous coronary intervention
Percutaneous Coronary Intervention - adverse effects
Percutaneous Coronary Intervention - methods
Prognosis
Risk Assessment
Risk Factors
Systemic inflammatory response index
Systemic Inflammatory Response Syndrome - epidemiology
Systemic Inflammatory Response Syndrome - etiology
Treatment Outcome
SummonAdditionalLinks – databaseName: Taylor & Francis Open Access (WRLC)
  dbid: 0YH
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LixQxEA6ygngR344vInht7UeSTo4qLoOw4sEFPYU81wXtXnp6fsf-ZauS9DizKHvwMjDdVdMZ6qtUpVP1hZDXAnADeYGrGul4xVpvKoWVAAJpAjrTd4Jjv_PJZ7E-ZZ--8aWacFPKKnENHTNRRJqr0bmN3SwVcW8hqoGbqhpWdy32UslOYBf5zRbRCpCuv693k3HbJ0ICVKlQZ2ni-dfPHISnxOJ_hcP0b5no1YLKvQh1fJfcKaklfZexcI_cCMN9cuukbJ4_IJdfphHL6uA2RY7vQMdIM5MzXIGnAzh-pU13OuXK2UATmSJ80sK_uqH44pYat50Ddch-YEB8oT2g2JE2nY0QDulFmEDIDGHcbv5Inu-VWD4kp8cfv35YV-U8hsrxjs2VEUIyy7vgYGaS0nAewMwyytb0Tai9iKyPjQwsChva2AVZe6esFY31BndcH5GjYRzCE0J9dEZFaa2vJTNeqVbaRjiOypDj-BVhixm0K2TleGbGT90snKbFehqtp4v1VuTNTu0is3Vcp_AebbwTRrLtdGGcznTxXW0hziMPH2eBsVh743xrubINM9H1Sq6I2keIntO7lpgPRtHdNQN4tcBJg2Pjbk22jG5hKacgd1Ag8zjDazfMjgvFOe9XpD8A3sH_OLwznP9I5OEKJnBY9T_9jzE_I7fxa6a7fE6O5mkbXkBqNtuXyfl-A5wdMYY
  priority: 102
  providerName: Taylor & Francis
Title Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention
URI https://www.tandfonline.com/doi/abs/10.1080/07853890.2022.2083671
https://www.ncbi.nlm.nih.gov/pubmed/35695557
https://www.proquest.com/docview/2675984791
https://pubmed.ncbi.nlm.nih.gov/PMC9225721
https://doaj.org/article/b130160754e44f0dacd2b59b14afc798
Volume 54
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lb9QwEIAt6AFxQbxZHisjcQ3kYTv2sa1arSq14kClcrL8hEqQVGn2d_QvM2Mny26FtBcuOThjJc5MPGN7_JmQTwLsBuICV1TS8YLV3hQKMwEEYgIa0zaC437n8wuxumRnV_xq66gvzAnLeOD84b5Y6GQRgsZZYCyW3jhfW65sxUx0rUrbfMHnzYOpqQ-u28QhAP_HC3DJ5bx3B6naUIZFMDascSeWbERb7XilBO-_hy79VwB6P49yyzGdPiVPpoiSHuaWPCMPQvecPDqf1sxfkLuvQ4_ZdHCbIto70D7SDHCGEng62MTvtNZOh5wwG2hiKMKVTtjVW4rztdS49RioQ-iBAfGZdkBxI9rwowcvSG_CAEKmC_369q_k9VZm5UtyeXry7XhVTMcwFI43bCyMEJJZ3gQHHZKUhvMA2pVR1qatQulFZG2sZGBR2FDHJsjSO2WtqKw3uND6ihx0fRfeEOqjMypKa30pmfFK1dJWwnGsDKGNXxA2q0G7iVGOR2X80tWMMp20p1F7etLegnzeVLvJkI59FY5QxxthZGynArA8PVme3md5C6K2LUSPaYol5vNQdLPnBT7O5qThf8ZFmqwZXcMITkHIoEDmdTavzWs2XCjOebsg7Y7h7bRj9053_TMxwxX02zDYf_s_Gv6OPMa2ZNzle3IwDuvwAUKz0S7Jw_L7apn-xWWaOfsDC-A2rg
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQkYAL4s3yNBLXQB62Yx8BUS3QrTi0UjlZfpZKkFRp9nfwl5mxk2W3AvXAJQd7JnE0M56xPfOZkNcC9AbiAldU0vGC1d4UCjMBBMIENKZtBMd659WhWB6zzyf8ZKsWBtMqcQ0dM1BEmqvRuHEzek6JewtuDexUlbC8q7GYSjYCy8ivc3C-eH1D-W25mY3rNiESIEuBPHMVz79es-OfEoz_JRDTv4WilzMqt1zU_h1ye4ot6busDHfJtdDdIzdW0-n5ffLr69BjXh10UwT5DrSPNEM5Qwt8HbTjZzp1p0NOnQ00oSnCk04ArBcUd26pcesxUIfwBwbIZ9wDiiVpw2kP_pCehwGITBf69cUfyrOtHMsH5Hj_49GHZTFdyFA43rCxMEJIZnkTHExNUhrOA8hZRlmbtgqlF5G1sZKBRWFDHZsgS--UtaKy3uCR60Oy1_VdeEyoj86oKK31pWTGK1VLWwnHkRmCHL8gbBaDdhNaOV6a8UNXM6jpJD2N0tOT9BbkzYbtPMN1XMXwHmW8IUa07dTQD6d6Ml5twdEjEB9ngbFYeuN8bbmyFTPRtUouiNrWED2mzZaYb0bRzRUDeDWrkwbLxuOaLBldw1pOQfCggOZRVq_NMBsuFOe8XZB2R_F2_mO3pzv7ntDDFczgsOx_8h9jfkluLo9WB_rg0-GXp-QWdmXsy2dkbxzW4TnEaaN9kQzxNyekNPo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQK1VcEOW5UMBIXAN52I59pMBqebTqgUpwsvxsK0GyymZ_B3-ZGSdZditQD1xysGcSRzPjGdsznwl5JUBvIC5wWSEdz1jpTaYwE0AgTEBl6kpwrHc-ORWLc_bpG5-yCVdjWiWuoeMAFJHmajTupY9TRtwb8GpgpiqH1V2JtVSyElhFvs8l-HpQ6fz7YjMZl3UCJECWDHmmIp5_vWbHPSUU_2sYpn-LRK8nVG55qPldcmcMLenbQRcOya3Q3CMHJ-Ph-X3y66xrMa0OuilifAfaRjogOUMLfB2U42c6dKfdkDkbaAJThCcd8VdXFDduqXHrPlCH6AcGyCfYA4oVad1FC-6QLkMHRKYJ7Xr1h_JqK8XyATmff_j6bpGN9zFkjlesz4wQklleBQczk5SG8wBillGWpi5C7kVkdSxkYFHYUMYqyNw7Za0orDd44vqQ7DVtEx4T6qMzKkprfS6Z8UqV0hbCcWSGGMfPCJvEoN0IVo53ZvzQxYRpOkpPo_T0KL0Zeb1hWw5oHTcxHKOMN8QItp0a2u5Cj7arLfh5xOHjLDAWc2-cLy1XtmAmulrJGVHbGqL7tNcSh4tRdHXDAF5O6qTBsPG0ZpCMLmEppyB2UEDzaFCvzTArLhTnvJ6Rekfxdv5jt6e5ukzg4QomcFj1P_mPMb8gB2fv5_rLx9PPT8lt7BmQL4_IXt-twzOI0nr7PNnhbyxQNCw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+systemic+inflammatory+response+index+in+patients+with+acute+coronary+syndrome+undergoing+percutaneous+coronary+intervention&rft.jtitle=Annals+of+medicine+%28Helsinki%29&rft.au=Han%2C+Kangning&rft.au=Shi%2C+Dongmei&rft.au=Yang%2C+Lixia&rft.au=Wang%2C+Zhijian&rft.date=2022-12-31&rft.eissn=1365-2060&rft.volume=54&rft.issue=1&rft.spage=1667&rft_id=info:doi/10.1080%2F07853890.2022.2083671&rft_id=info%3Apmid%2F35695557&rft.externalDocID=35695557
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0785-3890&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0785-3890&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0785-3890&client=summon